Evidence map›Paper›PMID 40581639›Full record

ArticleActa neuropathologica communications2025

Xenoline-polarized macrophages as an alternative in vitro model of tumor-associated macrophages in glioblastoma.

Hasan Alrefai, Benjamin Lin, Amr Elkholy, Manoj Kumar, Taylor L Schanel, Kevin J Lee, Patricia H Hicks, Joshua C Anderson, Gao Guo, Eun-Young Erin Ahn and 2 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Hasan AlrefaiDepartment of Radiation Oncology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Benjamin LinDivision of Neuropathology, Department of Pathology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Amr ElkholyDivision of Molecular and Cellular Pathology, Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Manoj KumarDepartment of Radiation Oncology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Taylor L SchanelDepartment of Radiation Oncology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Kevin J LeeDepartment of Radiation Oncology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Patricia H HicksDepartment of Radiation Oncology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Joshua C AndersonDepartment of Radiation Oncology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Gao GuoDepartment of Neurosurgery, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Eun-Young Erin AhnDivision of Molecular and Cellular Pathology, Department of Pathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
C Ryan MillerDivision of Neuropathology, Department of Pathology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
Christopher D WilleyDepartment of Radiation Oncology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, 35233, USA. cwilley@uabmc.edu.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008361 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YACOUBIAN, TALENE ALENE · 1992 to 2024
$16.8M
Glioblastoma tumor microenvironmental influence on acquired and inherent cancer therapy resistance.U01CA223976 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHEN, JAKE YUE, CUI, XIANGQIN · 2018 to 2022
$4.8M
Credentialing next-generation human glioma models for precision therapeuticsR01CA258248 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Frank Furnari, Christopher Ryan Miller · 2022 to 2026
$3.0M
Genetic and molecular basis of hematopoietic abnormalities in ZTTK syndromeR01HL168659 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Erin Eun-Young Ahn · 2023 to 2026
$2.1M
Therapeutic targeting mesenchymal transition in newly diagnosed and recurrent GBMR01NS134798 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Frank Furnari, Christopher Ryan Miller · 2024 to 2026
$1.9M
SON-mediated RNA splicing in glioblastomaR01CA236911 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHN, ERIN EUN-YOUNG · 2020 to 2024
$1.8M
Training Program in Brain Tumor BiologyT32NS121721 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Anita Borton Hjelmeland · 2024 to 2026
$503k
NCI NIH HHS R01 CA236911NCI NIH HHS R01 CA258248NCI NIH HHS U01 CA223976NHLBI NIH HHS R01 HL168659NIGMS NIH HHS T32 GM008361NIH/NCI R01CA236911NIH/NCI R01CA258248NIH/NCI U01CA223976NIH/NHLBI R01HL168659NIH/NIGMS T32GM008361NIH/NINDS 1T32NS121721-01A1NIH/NINDS R01NS134798NINDS NIH HHS R01 NS134798NINDS NIH HHS T32 NS121721O'Neal Invests Young Supporters Board Postdoctoral NextGen Scholars Award
6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs) are the most abundant non-cancerous cell type in glioblastoma (GBM) and heavily influence GBM biology, contributing to tumor progression, therapeutic resistance, immune evasion, and neovascularization. Current in vitro models that utilize IL-4/IL-13 stimulation fail to capture the transcriptional and functional heterogeneity of TAMs observed in vivo. In this study, we utilize a serum-free indirect co-culture model with patient-derived xenolines to polarize primary human macrophages and characterize their molecular and functional phenotypes. We demonstrate that xenoline-polarized macrophages diverge from classical M1/M2 states and instead adopt transcriptional signatures reflective of TAM subsets identified from patients. Notably, macrophages polarized with the radiation-therapy selected xenoline, JX14P-RT, exhibited gene expression patterns enriched for interferon response and hypoxia, mirroring recurrent GBM samples. In contrast, JX14P TAMs showed enrichment in phagocytic gene sets. Functional validation of these phenotypes revealed discrepancies between the transcriptionally predicted and observed phenotypes, emphasizing the importance of integrating phenotypic validation in sequencing studies. Altogether, our findings establish xenoline-polarized macrophages as a useful alternative to traditional models that can be used to study immune-interactions in vitro.

Indexed as

Brain NeoplasmsGlioblastomaMacrophagesTumor-Associated MacrophagesCoculture TechniquesHumans

Identifiers

PMID40581639
PMCPMC12205497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.